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Brain-specific glial fibrillary acidic protein (GFAP) has been suggested as a potential
biomarker for hypoxic ischemic encephalopathy (HIE) in newborns (1, 2). Previous studies
have shown increased levels in post-natal blood samples. However, its ability to guide
therapeutic intervention in HIE is unknown. Therapeutic hypothermia for HIE must be
initiated within 6 h of birth, therefore a clinically useful marker of injury would have to be
available immediately following delivery. The goal of our study was to examine the ability
of GFAP to predict grade of encephalopathy and neurological outcome when measured
in umbilical cord blood (UCB). Infants with suspected perinatal asphyxia (PA) and HIE
were enrolled in a single, tertiary maternity hospital, where UCB was drawn, processed,
and bio-banked at birth. Expression levels of GFAP were measured by ELISA. In total,
169 infants (83 controls, 56 PA, 30 HIE) were included in the study. GFAP levels were not
increased in UCB of case infants (PA/HIE) when compared to healthy controls or when
divided into specific grades of HIE. Additionally, no correlation was found between UCB
levels of GFAP and outcome at 36months.
Keywords: GFAP, hypoxic–ischemic encephalopathy, early diagnosis, biomaker, umbilical cord blood, therapeutic
interventions
INTRODUCTION
Perinatal asphyxia (PA) occurs when there is a disruption of oxygen delivery or blood supply to
the fetus around time of birth. PA, when severe, leads to hypoxic–ischemic encephalopathy (HIE)
in the neonatal period. HIE remains one of the leading clinical challenges faced in the neonatal
period and the greatest cause of acquired brain injury in term infants. To optimize outcomes in
neonatal HIE, early and accurate prediction of the degree of encephalopathy is vital. Neuroprotective
therapies must be commenced prior to the development of secondary brain injury, giving a narrow
therapeutic window of <6 h after delivery (3). Approximately 20 per 1000 live births will require
significant resuscitation at birth, and 10% of these infants will go on to have moderate-to-severe
encephalopathy. Using currently available assessment methods, it is estimated that 20% of infants
with significant hypoxic injury are clinically misclassified in the first hours of life and do not receive
hypothermia (4). Thus, there is a critical need for improved biomarkers for prediction of grade of
HIE and outcome (5).
Glial fibrillary acidic protein (GFAP), a monomeric intermediate filament protein predominant
in astrocytes is known to display increased expression following acute brain injury or CNS
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degeneration (6). Previous studies, primarily carried out in adults
have reported elevated levels of GFAP in traumatic brain injury,
specifically related to focal mass lesions (7). Its use as a biomarker
of HIE has previously been suggested, but the ability to differen-
tiate between PA and HIE at birth has not been examined (1).
Furthermore, little work has been carried out to determine the
use of GFAP as a marker of moderate/severe HIE specifically to
guide therapeutic intervention. To improve our ability to identify
infants who will benefit from therapeutic hypothermia in time for
effective intervention, any clinically useful biomarker will need to
be reliably altered at or soon after birth.
Therefore, our aim was to examine the use of GFAP as an
early clinical marker of HIE severity in full-term neonates by
determining expression in umbilical cord blood (UCB) samples
from healthy control infants, infants with perinatal asphyxia, and
infants with HIE. We also wished to examine correlation of UCB
GFAP with neurological outcome at 36months.
MATERIALS AND METHODS
Study Population
The BiHIVE Study (Biomarkers of HIE), including all
recruitment, consenting, and sample processing procedures,
was approved by the Clinical Research Ethics Committee of the
Cork Teaching Hospitals. Through this study, any infant with
suspected perinatal asphyxia or HIE in Cork UniversityMaternity
Hospital (CUMH), Ireland born between May 2009 and June
2011, was recruited as previously described (8). Briefly, infants
>36weeks gestational age were identified under strict enrollment
criteria: cord pH <7.1 and/or Apgar score 6 at 5min of life
and/or requiring intubation or CPR at birth. Once infants were
stable, parents were approached and informed about the study
and written consent was obtained for each infant. All clinical
and demographic information deemed relevant to the study was
then recorded prospectively. Healthy matched controls were
recruited through the BASELINE Study (www.baselinestudy.net),
a longitudinal birth cohort study based in Cork. Controls were
matched for sex, gestation, birth-weight, and gender, and all had
uncomplicated deliveries.
Cord Blood Sampling
Umbilical cord blood samples were collected immediately after
delivery of all infants in this study and processed within 3 h
following strict laboratory SOPs by a dedicated research team
who were available 24 h a day. Samples were stored at  80°C in
a monitored storage facility until analysis.
Neonatal Assessment
All infants with suspectedHIE received continuousmulti-channel
EEG monitoring. Our protocol for EEG monitoring has been
previously described (9). Clinical grade of encephalopathy was
assigned by a dedicated research fellow (BW) using the modified
Sarnat score. Additionally, grade was further confirmed using
EEG analysis with an experienced neonatal electroencephalogra-
pher (GB) who reviewed all EEG data. Therapeutic hypothermia
was commenced at the discretion of clinicians blinded to the
study data in all infants deemed to have moderate or severe
encephalopathy using the TOBY registry treatment criteria and
protocol (3).
GFAP Analysis
Glial fibrillary acidic protein analysis was carried out by Banyan
Biomarkers Inc., Alachua, FL, USA, on UCB serum samples
using Banyan Biomarker’s proprietary sandwich Enzyme-Linked
Immunosorbent Assays (ELISA) specific to GFAP. Detection lev-
els for the Banyan Assay range from 0.03 to 50 ng/ml. All samples
were run in duplicate and inter/intra assay variabilities of <10%
were reported.
Neurodevelopment Outcome
Where possible, developmental outcome was assessed at
36months of age using the Bayley Scales of Infant and Toddler
Development (Ed. III) (BSID-III) or the Ages and Stages
Questionnaire (Ed. III) Ages and Stages Questionnaire (ASQ3)
when the BSID-III was not possible due to reasons such as family
relocation, etc. The Ages and Stages Questionnaire (ASQ3) is
a parent-completed developmental screening questionnaire. It
consists of 30 developmental items organized into five areas:
Communication, Gross Motor, Fine Motor, Problem-Solving,
and Personal–Social. Questionnaires for each child’s appropriate
age interval were administered.
All BSID-III assessments were performed by a dedicated
research fellow blinded to the clinical history of the patients (CA).
For infants who underwent the assessment using the BSID-III,
outcome was determined using the composite scores of the three
subscales; cognitive, language, and motor. Infants were deemed
to have an abnormal outcome if they scored 85 in two or more
subscales or suffered neonatal death, cerebral palsy or autism. For
infants who were assessed with ASQ3 only, results were consid-
ered abnormal if scores indicated the need for further assessment,
falling >2 SD below the standardized mean, was advised in more
than one area.
Statistical Analysis
Statistical analysis was performed using IBM SPSS Statistics 22
(SPSS Inc., USA). Results were calculated using Student t-tests,
Mann–Whitney, and Kruskal–Wallis tests, as appropriate.
RESULTS
Study Population
In total, 169 infants were included in this study; 83 controls and 86
HIE cases. Of the 86 cases, 56 were classified as perinatal asphyxia
without HIE, 21 with mild HIE, 5 with moderate HIE, and 4 with
severe HIE, according to both themodified Sarnat assessment and
EEG classification. Population demographics for the entire cohort
are shown in Table 1.
GFAP Expression
On analysis of ELISA results, there was no statistically signifi-
cant difference in serum GFAP levels between case and control
infants within this study (p= 0.287). Similarly, when case infants
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were grouped as PA without HIE (n= 56) and infants with HIE
(n= 30), no difference was observed (p= 0.566, Figure 1). Addi-
tionally, when grade of HIE was specifically analyzed, no differ-
ence was observed between UCB levels of GFAP in mild, mod-
erate or severe HIE (0.199 0.095 ng/ml vs. 0.216 0.087 ng/ml
vs. 0.168 0.258 ng/ml, p= 0.931). Finally, when grouped as
TABLE 1 | Comparison of population demographics for entire study cohort
(n=169).
Control Perinatal asphyxia HIE
n=83 n=56 n=30
Gestation (week+day) 40+ 3
(1+ 1)
40+ 3
(2+ 1)
40+ 3
(2+5)
Birth weight (g) 3518 (447.4) 3596 (533.8) 3495 (516.5)
Gender (M/F) 48/35 35/21 20/10
Mode of delivery
SVD 31 (37%) 18 (32%) 6 (20%)
Instrumental 36 (43%) 28 (50%) 15 (50%)
Elective cesarean section 4 (5%) : : : : : :
Emergency cesarean section 12 (15%) 10 (18%) 9 (30%)
1min Apgara 9 (9–9) 5 (3–7) 3 (1–5)
5min Apgara 10 (9–10) 8 (6–9) 5 (3–7)
Cord pHa 7.21
(7.15–7.26)
7.04
(6.99–7.09) 0.08
6.99
(6.91–7.08)
Infants separated into controls, infants with perinatal asphyxia, and infants with
hypoxic–ischemic encephalopathy (HIE). Data expressed as mean (SD) or median
(interquartile rage) where appropriate.
aRepresents a p value of <0.001 between groups calculated using Kruskal–Wallis or
Mann–Whitney U tests.
M, male; F, female; SVD, spontaneous vaginal delivery.
FIGURE 1 | Boxplot representing umbilical cord blood (UCB) levels of GFAP (ng/ml) following commercial ELISA analysis. Infants grouped as healthy
controls (n= 83), infants with perinatal asphyxia (PA) without HIE (n= 56), and infants with clinical and electrographically confirmed HIE (n=30). No significant
alteration was detected between groups (p= 0.566).
infants who would be deemed eligible for therapeutic hypother-
mia (n= 9) vs. those who would not (n= 160), again no increase
was observed (p= 0.919, Figure 2).
Outcome at 36Months of Age
In the total study population, outcome at 36months was available
in 116/169 (69%) infants [61 (73%) controls, 32 PA (57%), and 23
(77%) HIE]. Of these, 70 infants underwent outcome assessment
using the Bayley Scales of Infant and Toddler Development (Ed.
III). The remaining 46 infants underwent assessment using the
Ages and Stages Questionnaire (Ed. III-ASQ3). Further break-
down of grade of HIE and outcome is available in Table 2. When
classed as infants with a normal outcome vs. infants with an
abnormal outcome at 36months, no discernable elevation in UCB
GFAP levels was observed Figure 3.
DISCUSSION
Increased levels of GFAPhave been shown to be useful biomarkers
of adult brain pathology (6, 10–15). In spite of this, investigations
into its use in the neonatal field have been somewhat limited,
with only a small number of publications suggesting GFAP as a
biomarker in HIE with the ability to distinguish between grades
of HIE (1, 2, 16–18). While these studies provided promising
results, they also cited major limitations with regard to sample
size and sample availability throughout. Post-natal blood samples
were predominately used, with few studies determining levels in
UCB,which is arguably the earliest possible source for a biomarker
of HIE. However, as HIE is known to encompass a two stage
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FIGURE 2 | Boxplot representing further analysis of umbilical cord blood (UCB) levels of GFAP (ng/ml) in infants which would be deemed eligible for
therapeutic hypothermia (TH; moderate and severe hypoxic–ischemic encephalopathy, n=9) and infants who would not meet the eligible criteria
(Non-TH; controls, perinatal asphyxia, and mild hypoxic–ischemic encephalopathy, n=160). No significant elevation in GFAP levels was observed
(p=0.919).
TABLE 2 | Comparison of neurodevelopmental follow-up at 36months of
age, primarily using the Bayley Scales of Infant and Toddler Development
(Ed. III) (n=70) or the Ages and Stages Questionnaire (Ed. III) (n=46).
Outcome Control
(n=61)
PA
(n=32)
Mild HIE
(n=15)
Mod/sev HIE
(n=8)
Normal 60 30 9 4
Abnormal 1 2 6 4a
GFAP (ng/ml) 0.20
(0.04–0.55)
0.22
(0.04–0.14)
0.20
(0.08–0.36)
0.23
(0.05–0.63)
No alteration in GFAP levels was detected in the umbilical cord blood from healthy control
infants, infants with perinatal asphyxia (PA), infants with mild HIE or infants with moderate
or severe (Mod/Sev) HIE. GFAP levels (nanogram per milliliter) are expressed as mean
(range).
aOutcome defined by clinical diagnosis of CP or death.
evolvingmechanism of injury, the time at whichGFAP levelsmost
represent degree of injury must be established.
In this study, our goal was to add to the current knowledge
available for this promising biomarker specifically in relation to
HIE. We aimed to validate the use of GFAP as a marker of HIE
severity specifically and to overcome the previously cited limita-
tions, mainly through the use of a larger, carefully defined popula-
tion cohort and through the use of UCB as our sample source. All
our samples are collected and processed in an operational biobank
following strict SOPs. Additionally, UCB represents the earliest
possible blood sample available after delivery. Although it is not
taken directly from the infant, it provides a snapshot of an infant’s
circulation at the time of delivery and can therefore offer a unique
insight into the neonatal condition. This sample is relatively easy
to obtain, does not involve an invasive procedure to an already
stressed newborn and could potentially classify infants depending
on degree of injury, contributing to rapid and reliable therapeutic
decision-making.
A large collection of previously published research focused
on GFAP and CNS damage in general is available; however, a
recent review of neonatal biomarkers by Bersani et al. (19) called
for further work to investigate the validity of this protein with
a particular focus on outcome. We discovered no significant
alterations in GFAP expression between our case and control
groups or between different grades of HIE. Additionally, we
found no correlation of GFAP levels with outcome at 36months
of age.
Our findings initially seem to contradict previously published
research regarding the potential use ofGFAP as an early biomarker
of moderate/severe HIE. However, most studies to date have
focused on post-natal samples, with significant elevation seen
after 6–12 h (1, 18). More recently, a study focused on mixed cord
samples in a historical cohort has shown no difference in serum
GFAP levels between controls and infants with moderate-severe
HIE (20). This is in keepingwith previouswork in adult TBIwhere
peak levels occur at 12 h post-injury.
While there is good evidence that GFAPmay be a usefulmarker
of HIE severity in samples taken after six post-natal hours, we
have not shown altered levels in UCB samples. This is the first
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FIGURE 3 | Comparison of umbilical cord blood (UCB) levels of GFAP (nanogram per milliliter) from infants with a normal outcome at 24–36months
(n=103) compared to those with an abnormal outcome (n=13), presented as a box plot. A significant difference was not detected between groups
(p=0.919).
prospective, carefully defined cohort study to focus on GFAP in
UCB. This may limit the usefulness of GFAP as a biomarker to
guide therapeutic intervention.
CONCLUSION
Serum GFAP is not altered in the UCB samples of infants with
perinatal asphyxia, with or without clinical and electrographic
HIE, compared to normal controls. GFAP therefore may not be
the ideal early biomarker to predict eligibility for therapeutic
intervention.
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